ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients …

By /

Bexobrutideg (NX-5948) is a novel Bruton's tyrosine kinase (BTK) degrader that degrades BTK rather than inhibiting BTK function. The ongoing phase Ia/ …

More »

Leave a Comment

Your email address will not be published. Required fields are marked *

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by
Scroll to Top